AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 180 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $6,097,000 | -66.3% | 451,631 | -39.7% | 1.17% | -56.7% |
| Q4 2019 | $18,094,000 | -13.8% | 748,597 | -31.4% | 2.70% | -25.4% |
| Q3 2019 | $20,979,000 | -25.7% | 1,091,534 | +14.2% | 3.62% | +7.1% |
| Q2 2019 | $28,251,000 | -29.2% | 956,036 | +13.8% | 3.38% | -29.6% |
| Q1 2019 | $39,898,000 | -2.5% | 839,954 | -25.9% | 4.80% | -13.8% |
| Q4 2018 | $40,936,000 | -14.5% | 1,133,954 | +45.9% | 5.56% | +9.5% |
| Q3 2018 | $47,853,000 | +15.0% | 777,470 | +26.2% | 5.08% | +9.2% |
| Q2 2018 | $41,602,000 | +42.4% | 615,870 | +14.3% | 4.65% | +45.2% |
| Q1 2018 | $29,220,000 | +32.6% | 538,618 | +46.0% | 3.20% | +16.4% |
| Q4 2017 | $22,036,000 | +21.4% | 368,797 | -1.2% | 2.75% | +17.8% |
| Q3 2017 | $18,147,000 | -14.2% | 373,396 | -7.3% | 2.34% | +1.0% |
| Q2 2017 | $21,161,000 | +19.8% | 402,674 | +3.4% | 2.31% | +12.2% |
| Q1 2017 | $17,660,000 | +98.3% | 389,423 | +65.5% | 2.06% | +108.9% |
| Q4 2016 | $8,906,000 | -5.3% | 235,298 | -5.6% | 0.99% | +6.9% |
| Q3 2016 | $9,405,000 | +504.4% | 249,200 | +181.9% | 0.92% | +473.3% |
| Q2 2016 | $1,556,000 | – | 88,400 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |